Shattuck Labs Inc
$ 7.35
2.51%
16 Apr - close price
- Market Cap 541,921,000 USD
- Current Price $ 7.35
- High / Low $ 7.41 / 7.12
- Stock P/E N/A
- Book Value 1.30
- EPS -0.70
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.35 %
- ROE -0.60 %
- 52 Week High 7.68
- 52 Week Low 0.71
About
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapies for the treatment of cancer and autoimmune diseases in the United States. The company is headquartered in Austin, Texas.
Analyst Target Price
$10.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-17 | 2025-11-06 | 2025-08-14 | 2025-04-30 | 2025-02-26 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-02-29 | 2023-11-09 | 2023-08-10 | 2023-05-09 |
| Reported EPS | -0.12 | -0.14 | -0.24 | -0.27 | -0.37 | -0.33 | -0.42 | -0.37 | -0.41 | -0.65 | -0.5 | -0.49 |
| Estimated EPS | -0.1316 | -0.1432 | -0.245 | -0.2825 | -0.3188 | -0.42 | -0.41 | -0.45 | -0.57 | -0.52 | -0.52 | -0.63 |
| Surprise | 0.0116 | 0.0032 | 0.005 | 0.0125 | -0.0512 | 0.09 | -0.01 | 0.08 | 0.16 | -0.13 | 0.02 | 0.14 |
| Surprise Percentage | 8.8146% | 2.2346% | 2.0408% | 4.4248% | -16.0602% | 21.4286% | -2.439% | 17.7778% | 28.0702% | -25% | 3.8462% | 22.2222% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.14 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: STTK
2026-04-12 12:40:27
This article reports that Shattuck Labs (STTK) has received a price target increase of 37.93%, raising it to $10.20. The article is very brief and does not provide further details or analysis regarding the reasons for this price target adjustment.
2026-04-09 20:39:41
Shares of Shattuck Labs (NASDAQ:STTK) surged 8.4% after several Wall Street analysts provided positive commentary and increased price targets for the clinical-stage biotech company. This optimism stems from the company's focus on developing immunotherapeutic vaccines for substance use disorders, particularly opioids. The stock's rally was driven by new 'overweight' and 'buy' ratings from Piper Sandler and Needham & Company, respectively, and an increased price target from Wedbush.
2026-04-08 11:10:12
This article announces an ARS SEC filing by Shattuck Labs, Inc. (STTK) on April 8, 2026. The filing is categorized with low impact and neutral sentiment, and the full document is available as a PDF via the SEC EDGAR source. The article also provides a brief overview of Shattuck Labs, including its market cap, industry, and recent news and SEC filings.
2026-04-08 10:10:12
Shattuck Labs will hold its 2026 virtual annual stockholder meeting on May 28, 2026, where shareholders will vote on core governance matters including the election of three Class III directors, ratification of KPMG LLP as independent auditor, and advisory votes on executive compensation and its frequency. A key proposal is the approval of an amended and restated 2020 Equity Incentive Plan, which seeks to expand the share pool to maintain long-term equity capacity for employees, directors, and consultants, reflecting the company's changed capital structure following recent financings. The Board recommends voting "FOR" all proposals and for annual "say-on-pay" votes.
2026-04-06 07:10:13
Shattuck Labs, Inc. (NASDAQ: STTK) announced its participation in two upcoming investor conferences in March 2026. CEO Taylor Schreiber will present at the TD Cowen 46th Annual Health Care Conference on March 2nd and participate in one-on-one meetings at the Leerink Partners 2026 Global Health Care Conference on March 10-11. The company, a clinical-stage biotechnology firm, specializes in developing DR3-blocking antibodies for inflammatory and immune-mediated diseases, with its lead program being SL-325.
2026-04-04 16:11:04
Wall Street analysts have a "Moderate Buy" rating for Shattuck Labs Inc (STTK.O), with an average price target of $8.33. Citi maintained a Neutral rating but raised its price target to $7, citing an "upside 90-day catalyst watch" for upcoming Phase 1 data. Wedbush maintained an Outperform rating and increased its price target to $8, expecting low ADA rates in the healthy volunteer data for SL-325.
